<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805896</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-1001</org_study_id>
    <nct_id>NCT00805896</nct_id>
  </id_info>
  <brief_title>Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma</brief_title>
  <official_title>Effectiveness and Safety Study of TACE Plus Oral Songyou Granule for Unresectable HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule&#xD;
      can inhibit HCC cells grow, and HCC metastasis. Hypothesis of this study is that TACE plus&#xD;
      Songyou Granule will improve outcome in patients with advanced hepatocellular carcinoma (HCC)&#xD;
      compared with TACE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome Measures:&#xD;
&#xD;
      To evaluate the effect of TACE plus Songyou Granule or TACE plus placebo on TTP&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
        -  Overall survival (OS)&#xD;
&#xD;
        -  Progression Free Survival (PFS)&#xD;
&#xD;
        -  The overall response rate&#xD;
&#xD;
        -  Time to symptomatic Progression&#xD;
&#xD;
        -  In an exploratory manner the relative TTP, TTSP, RR and overall survival between the 2&#xD;
           study populations&#xD;
&#xD;
        -  Overall response duration and time to objective response&#xD;
&#xD;
        -  Overall disease control rate&#xD;
&#xD;
        -  The safety, tolerability, and adverse event profiles of the two treatment regimens used&#xD;
           in this trial&#xD;
&#xD;
      Enrollment: 260 Study Start Date: January 2009 Study Completion Date: December 2010 Primary&#xD;
      Completion Date: December 2010 (Final data collection date for primary outcome measure)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to tumor progression(TTP)</measure>
    <time_frame>Dec 2008 to Dec 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Dec 2008 to Dec 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Unresectable</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Songyou Granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Songyou</intervention_name>
    <description>4g/pack</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>4g/pack</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults patients (≥ 18 years of age) with a diagnosis of HCC which is not amenable to&#xD;
             surgical resection or local ablative therapy&#xD;
&#xD;
          -  Histological confirmed HCC or clinical/laboratory diagnosis of HCC or nodules larger&#xD;
             than 2 cm with typical vascular features or AFP &gt; 200&#xD;
&#xD;
          -  Patient must have quantifiable disease limited to the liver&#xD;
&#xD;
          -  Patients must have at least one tumor lesion that meets both of the following&#xD;
             criteria:&#xD;
&#xD;
               -  The lesion can be accurately measured in at least one dimension according to&#xD;
                  RECIST criteria&#xD;
&#xD;
               -  The lesion has not been previously treated with surgery, radiation therapy,&#xD;
                  radiofrequency ablation, percutaneous ethanol or acetic acid injection, or&#xD;
                  cryoablation.&#xD;
&#xD;
          -  ECOG performance status (PS) &lt;2&#xD;
&#xD;
          -  No prior targeted antiangiogenic therapy. Metronomic chemotherapies are allowed. At&#xD;
             least 4 weeks since prior systemic chemotherapy&#xD;
&#xD;
          -  No significant baseline liver dysfunction. Cirrhotic status of Child-Pugh class A or B&#xD;
&#xD;
          -  No significant renal impairment (creatinine clearance &lt; 30 mL/minute) or patients on&#xD;
             dialysis&#xD;
&#xD;
          -  The following laboratory parameters:&#xD;
&#xD;
               -  Platelet count ≥ 50,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 2 mg/dL&#xD;
&#xD;
               -  ASL and AST ≤ 5 x upper limit of normal&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
               -  INR ≤ 1.5 or a PTT within normal limits&#xD;
&#xD;
          -  Ability to understand the protocol and to agree to and sign a written informed consent&#xD;
             document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC&#xD;
             except cervical carcinoma in situ, treated basal-cell carcinoma of the skin,&#xD;
             superficial bladder tumors (Ta, Tis &amp; T1), and any cancer curatively treated &gt; 3 years&#xD;
             prior to entry is permitted&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Child-Pugh C hepatic impairment&#xD;
&#xD;
          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  Known central nervous system tumors including metastatic brain disease&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Substance abuse (current), psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Known or suspected allergy to the investigational agents or any agent given in&#xD;
             association with this trial.&#xD;
&#xD;
          -  Patients unable to swallow oral medications.&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed within seven days prior to the start of the study&#xD;
             drug. Both men and women enrolled in this trial must use adequate barrier birth&#xD;
             control measures during the course of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao-You Tang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boheng Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Cancer Institute and Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>December 30, 2008</last_update_submitted>
  <last_update_submitted_qc>December 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Boheng Zhang/Liver Cancer Institute</name_title>
    <organization>Fudan University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

